Physician profile
Nelson Yu
NPI 1447297601
$8,497.50
in general payments reported to CMS, 2019-2025
31 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $1,421 · 2021: $1,661 · 2022: $1,782 · 2023: $754 · 2024: $911 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.26 |
| Education | $280.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,750.65 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,154.18 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $641.82 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $482.95 | 2019-2025 | Prolastin-C Liquid, Gamunex-C |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.19 | 2019-2025 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $355.15 | 2020-2021 | |
| Genzyme Corporation | $274.12 | 2023-2025 | |
| Insmed, INC. | $219.66 | 2019-2025 | Arikayce |
| Shire North American Group INC | $191.69 | 2019 | |
| Amgen INC. | $163.57 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $109.61 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Abbvie INC. | $99.22 | 2019-2025 | Ubrelvy |
| Sunovion Pharmaceuticals INC. | $80.61 | 2019 | |
| Harmony Biosciences LLC | $74.33 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $71.81 | 2019-2025 | Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $33.46 | 2022 | |
| Phathom Pharmaceuticals, INC. | $33.07 | 2025 | Voquezna |
| Electromed, INC. | $28.45 | 2025 | Smartvest |
| Pfizer INC. | $23.97 | 2019 | |
| United Therapeutics Corporation | $20.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.45 | 2019 | |
| Mylan Specialty L.P. | $17.54 | 2019 | |
| Exact Sciences Corporation | $16.32 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $16.12 | 2025 | Zepbound, Mounjaro |
| Verona Pharma, INC. | $15.00 | 2025 | Ohtuvayre |
| Medtronic, INC. | $14.95 | 2021 | |
| Inspire Medical Systems, INC. | $14.42 | 2025 | Inspire |
| Gilead Sciences, INC. | $12.21 | 2019 | |
| Phadia US INC. | $11.44 | 2019 | |
| Astellas Pharma US INC | $5.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.